Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
66 shown of 8,360 total abstracts
  1. Abstract 19232026-04-05 · 13:15 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-277
    H. Borghaei, L. Paz-Ares, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 19642026-04-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-886 study)
    N. Rizvi, F. Andre, S. Modi, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 15952026-04-04 · 18:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-305
    J. Brahmer, C. Robert, S. Modi · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 11622026-04-02 · 21:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-353
    S. Tolaney, E. Winer, M. Krop, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 12292026-04-02 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-732
    F. Andre, G. Curigliano, A. Spira, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 17152026-04-04 · 15:45 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-103
    E. Winer, S. Modi · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 19282026-04-02 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    F. Andre, C. Robert · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 17322026-04-01 · 16:30 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    M.C. Garassino, H. Rugo, G. Curigliano, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 12662026-04-03 · 21:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-473
    C. Saura, P. Schmid, H. Borghaei, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 13722026-04-03 · 19:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-481 study)
    N. Rizvi, G. Curigliano, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 17202026-04-04 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    J. Cortes, C. Saura, S. Tolaney, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 16452026-04-03 · 15:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    C. Robert, P. Schmid, R. Herbst, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 19592026-04-02 · 14:45 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    G. Curigliano, C. Saura, E. Winer, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 16792026-04-02 · 21:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-774 study)
    S. Peters, T. Mok · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 14372026-04-04 · 20:30 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-580 study)
    T. Mok, M. Krop, S. Modi · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 11122026-04-05 · 15:15 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    H. Borghaei, S. Modi, M.C. Garassino, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 16572026-04-03 · 15:00 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    G. Curigliano, H. Rugo, M. Reck · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 19402026-04-05 · 13:30 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-486
    T. Mok, L. Paz-Ares, S. Antonia · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 15172026-04-04 · 18:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-669
    G. Curigliano, F. Andre · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 12992026-04-04 · 16:00 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    G. Curigliano, S. Antonia, H. Borghaei, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 17042026-04-05 · 13:30 CT · E450
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-385
    N. Rizvi, T. Mok, M. Reck, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 15972026-04-02 · 19:30 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-847
    P. Schmid, M. Krop, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 11612026-04-01 · 18:30 CT · Hall B1
    PALOMA-326: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    F. Andre, M.C. Garassino, J. Cortes · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 11232026-04-01 · 14:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-598
    A. Spira, S. Antonia, N. Rizvi, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 15662026-04-04 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-29 study)
    T. Mok, J. Cortes, E. Winer, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 17302026-04-04 · 18:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-168
    L. Paz-Ares, R. Herbst, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 17052026-04-03 · 15:45 CT · S406
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-169
    S. Tolaney, H. Rugo, N. Rizvi, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 15522026-04-01 · 18:00 CT · S406
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-293
    J. Cortes, M.C. Garassino, N. Rizvi, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  29. Abstract 15812026-04-04 · 20:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-372
    M. Reck, E. Winer, A. Spira, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 16762026-04-02 · 21:15 CT · Arie Crown Theater
    MONARCH-455: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Modi, M.C. Garassino, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 17212026-04-05 · 19:45 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M. Krop, J. Cortes · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 12292026-04-02 · 21:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-604
    T. Mok, A. Spira, S. Tolaney, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 16222026-04-02 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-891
    C. Saura, G. Curigliano, S. Tolaney, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 12872026-04-02 · 15:30 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-862 study)
    G. Curigliano, M.C. Garassino, F. Andre · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 11952026-04-03 · 21:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-571 study)
    F. Andre, M. Krop, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 15402026-04-02 · 21:00 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-567
    M. Krop, L. Paz-Ares, S. Modi, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 13152026-04-01 · 14:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-867
    M. Reck, S. Modi · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 19402026-04-04 · 19:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-485 study)
    J. Brahmer, M. Reck, L. Paz-Ares · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 11902026-04-05 · 15:15 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-558
    M. Krop, C. Saura, S. Tolaney · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 15102026-04-03 · 21:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-157 study)
    C. Robert, N. Rizvi · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 13602026-04-03 · 21:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-354 study)
    L. Paz-Ares, S. Antonia, C. Robert, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 18942026-04-04 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-380 study)
    C. Saura, F. Andre, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 18312026-04-03 · 14:15 CT · Hall B1
    ASCENT-941: Trodelvy (sacituzumab govitecan) 2L in TNBC
    M.C. Garassino, E. Winer, J. Cortes, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 18852026-04-01 · 16:00 CT · Hall B1
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-870
    J. Cortes, H. Rugo, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 11262026-04-03 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-6
    T. Mok, R. Herbst, C. Saura, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 16402026-04-03 · 16:30 CT · E450
    Quality of life outcomes with Keytruda in patients with TNBC
    T. Mok, M. Krop, J. Brahmer, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 11582026-04-05 · 13:30 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    J. Brahmer, M. Reck, H. Rugo · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 14552026-04-03 · 13:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-515
    C. Robert, C. Saura, M. Reck, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 19122026-04-05 · 18:45 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    C. Saura, S. Tolaney, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 16052026-04-02 · 21:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-796 study)
    R. Herbst, N. Rizvi, L. Paz-Ares, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 11612026-04-05 · 18:00 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-751
    J. Brahmer, J. Cortes, C. Robert · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 19092026-04-05 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-102 study)
    C. Saura, S. Antonia · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 15342026-04-05 · 20:00 CT · S406
    MONALEESA-970: Kisqali (ribociclib) 1L in HR+ breast cancer
    H. Rugo, J. Cortes, L. Paz-Ares, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 11172026-04-05 · 13:30 CT · E450
    PALOMA-441: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    S. Modi, G. Curigliano, M. Krop, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 11202026-04-01 · 15:30 CT · S100A
    MONALEESA-551: Kisqali (ribociclib) maintenance in HR+ breast cancer
    R. Herbst, J. Brahmer, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 11092026-04-04 · 21:15 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-518
    L. Paz-Ares, S. Antonia, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 14182026-04-01 · 16:15 CT · Hall B1
    OlympiA-769: Lynparza (olaparib) 3L+ in HR+ breast cancer
    M.C. Garassino, S. Peters, H. Borghaei, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 13842026-04-04 · 13:30 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    S. Tolaney, F. Andre · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 16162026-04-04 · 15:00 CT · S100A
    DESTINY-Breast-834: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    N. Rizvi, M. Reck, L. Paz-Ares, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 11442026-04-03 · 16:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-112
    E. Winer, H. Rugo, S. Antonia · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 14552026-04-02 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-257
    H. Borghaei, M. Reck, R. Herbst, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 11132026-04-01 · 15:45 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-709
    M. Krop, S. Peters, M. Reck · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 19542026-04-03 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-80 study)
    J. Brahmer, R. Herbst, H. Borghaei, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 17072026-04-02 · 21:00 CT · S100A
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-47
    H. Rugo, J. Brahmer, R. Herbst, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 17052026-04-04 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-97 study)
    N. Rizvi, T. Mok, C. Robert · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 19002026-04-01 · 19:45 CT · S100A
    IMpower-424: Tecentriq (atezolizumab) 1L in TNBC
    G. Curigliano, H. Borghaei, S. Tolaney · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.